Innovations in Drug Delivery Systems for Biologics: Enhancing Stability and Targeted Delivery for Next-Generation Therapeutics
Abstract
The aim of this study is to explore and evaluate recent innovations in drug delivery systems (DDS) for biologics, focusing on enhancing stability and targeted delivery to improve the efficacy and safety of next-generation therapeutics. The most recent developments in a variety of DDS, such as nanoparticles, microneedles, hydrogels, and biodegradable polymers, were examined in depth. Information from peer-audited diaries, clinical preliminaries, and mechanical reports were blended to survey the presentation of these frameworks concerning dependability, designated conveyance, patient consistence, and controlled discharge. A radar chart was used in a comparative analysis to show the advantages and disadvantages of each DDS. Utilizing cutting-edge DDS, our analysis revealed significant improvements in the stability and targeted delivery of biologics. Nanoparticles exhibited the most elevated precision in designated conveyance at 92% and showed a 85% improvement in soundness. With an 88% satisfaction rate and moderate improvements in other criteria, microneedles achieved the highest level of patient compliance. Biodegradable polymers provided a balanced enhancement across all criteria, with 88% improvements in stability, 87% improvements in targeted delivery, and 89% improvements in controlled release for hydrogels. Nanoparticles lost only 6% of their stability, microneedles lost 10% of their controlled release, hydrogels lost 7% of their stability, and biodegradable polymers lost 5% of their patient compliance across all of these systems. The stability and precise delivery of biologics have been significantly improved by advancements in drug delivery systems. Hydrogels and microneedles, on the other hand, provide advantages in controlled release and patient compliance. Biodegradable polymers and nanoparticles are promising for maintaining drug integrity and targeting particular sites. In order to overcome the limitations that exist currently and enhance the therapeutic outcomes of biologics, future research ought to concentrate on hybrid strategies that combine the advantages of multiple DDS.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Advanced drug delivery platforms can improve solubility, stability, bioavailability, and site-specific targeting, increasing treatment efficacy while minimizing systemic exposure.
“More broadly, advanced drug delivery platforms can improve solubility [22], stability [23], bioavailability [24], and site‐specific targeting [25], ultimately increasing treatment efficacy while minimizing systemic exposure.”
From Statins as Antifungal Agents: A Review on Drug Repurposing and Nanotechnology-Driven Delivery Strategies (2025) · cites this paper as [23]
Cites
The Future of Peptide‐based Drugs
Craik, D. J., Fairlie, D. P., Liras, S. I., & Price, D. A. (2012) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12055 · Cited by 1,984 · see citing works
Extracellular vesicles as a next-generation drug delivery platform
Herrmann, I. K., Wood, M. J. A., & Fuhrmann, G. (2021) · Nature Nanotechnology · doi:10.1038/s41565-021-00931-2 · Cited by 1,951 · see citing works
Next generation antibody drugs: pursuit of the 'high-hanging fruit'
Carter, P. J., & Lazar, G. A. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.227 · Cited by 760 · see citing works
Engineering the next generation of cell-based therapeutics
Bashor, C. J., Hilton, I. B., Bandukwala, H. S., Smith, D. M., & Omid Veiseh, A. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00476-6 · Cited by 448 · see citing works
Advances in nanomaterial-based targeted drug delivery systems
Cheng, X., Xie, Q., & Sun, Y. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1177151 · Cited by 419 · see citing works
The Dawn of a New Era: Targeting the “Undruggables” with Antibody-Based Therapeutics
Qian, L., Lin, X., Gao, X., Khan, R. U., Liao, J., Du, S., Ge, J., Zeng, S., & Yao, S. Q. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.2c00915 · Cited by 156 · see citing works
Moncalvo, F., Espinoza, M. I. M., & Cellesi, F. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00089 · Cited by 106 · see citing works
Ragelle, H., Rahimian, S., Guzzi, E. A., Westenskow, P. D., Tibbitt, M. W., Schwach, G., & Langer, R. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113990 · Cited by 72 · see citing works
Innovations in Oral Therapies for Inflammatory Bowel Disease
Ma, C., Battat, R. J., Dulai, P. S., Parker, C. E., Sandborn, W. J., Feagan, B. G., & Jairath, V. (2019) · Drugs · doi:10.1007/s40265-019-01169-y · Cited by 70 · see citing works
Limeres, M. J., Moretton, M. A., Bernabeu, E., Chiappetta, D. A., & Cuestas, M. L. (2018) · Materials Science and Engineering C · doi:10.1016/j.msec.2018.11.001 · Cited by 46 · see citing works
Emerging skin-targeted drug delivery strategies to engineer immunity: A focus on infectious diseases
Korkmaz, E., Balmert, S. C., Carey, C. D., Erdös, G., & Falo, L. D. (2020) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2021.1823964 · Cited by 31 · see citing works
Drug delivery as a sustainable avenue to future therapies
Fuhrmann, G. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.01.045 · Cited by 28 · see citing works
Biological therapeutic modalities
Chhabra, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821972-0.00015-0 · Cited by 16 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
The Importance of Disruptive Innovation in the Allergy Immunology Clinic
Shaker, M. S., Golden, D. B. K., Greenhawt, M., Oppenheimer, J., Bernstein, J. A., Conway, A. E., Verdi, M., Anagnostou, A., Abrams, E. M., Blatman, K. S. H., et al. (2025) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2025.05.057 · Cited by 11 · see citing works
e Silva, D. M., de Souza Lacerda, L., de Souza Andrioli, A., Braz, W. R., Campos, L. M., de Paiva, M. R. B., Pittella, F., Fabri, R. L., & Tavares, G. D. (2025) · Fundamental & Clinical Pharmacology · doi:10.1111/fcp.70046 · Cited by 7 · see citing works
Khatun, B., Rizwana, S., Mondal, N. J., & Chowdhury, D. (2025) · IGI Global eBooks · doi:10.4018/979-8-3373-1047-3.ch001 · Cited by 1 · see citing works
Nam, N. T. H., Vu, N. H., Dat, N. M., Huong, L. M., & Hiếu, N. H. (2026) · Langmuir · doi:10.1021/acs.langmuir.6c00450 · Cited by 1 · see citing works
Pishgahzadeh, E., Bozorgchami, N., Talebi, M., Masoudifar, R., Ahmadi, M., & Ghorbani-Bidkorpeh, F. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.126319
Antisense Oligonucleotides as Precision Therapies for Neurodegenerative Diseases: A Narrative Review
Mohebbi, S., Ghanbari, M., & Hassanlou, M. (2026) · Jentashapir Journal of Cellular and Molecular Biology · doi:10.5812/jjcmb-169275
- Authors
- Maharaja Agrasen Himalayan Garhwal University, P., Kumar, P., Goel, A., Maharaja Agrasen Himalayan Garhwal University, P., Dash, B., Amity Institute of Pharmacy, A. U., Rishishwar, P., Maharaja Agrasen Himalayan Garhwal University, P., S, J., Alpha Pharma Industries, K. 2., Vivekanand Suryawanshi, M., Sandip Institute of Pharmaceutical Sciences (SIPS), N., Rishishwar, S., Maharaja Agrasen Himalayan Garhwal University, P., Asokan, N., & Department of Life Science, S.
- Affiliations
- Maharaja Agrasen Himalayan Garhwal University (IN)
- Amity University (IN)
- Sri Sathya Sai University for Human Excellence (IN)
- Venue
- Chinese Journal of Applied Physiology
- Published
- 2025
- Volume
- 41
- Pages
- e20250001
- ISSN
- 1000-6834 (ISSN-L)
- OpenAlex
- W4406038489
- Cited by
- 6
- References
- 13
- Citations by year
- 2026: 2 · 2025: 4
- FWCI
- 2.56
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Chinese Journal of Applied Physiology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advancements in Transdermal Drug Delivery
- Keywords
- drug delivery systems, biologics, drug stability, targeted delivery, nanoparticles, microneedles, hydrogels, biodegradable polymers, controlled release, medication adherence
- MeSH terms
- Biological Products, Drug Stability, Humans, Needles, Polymers, Drug Delivery Systems, Hydrogels, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
